Equities analysts forecast that Kadmon Holdings Inc (NYSE:KDMN) will report sales of $2.75 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Kadmon’s earnings, with the lowest sales estimate coming in at $260,000.00 and the highest estimate coming in at $5.23 million. Kadmon posted sales of $230,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 1,095.7%. The firm is scheduled to issue its next earnings results on Thursday, March 5th.
According to Zacks, analysts expect that Kadmon will report full-year sales of $2.59 million for the current fiscal year, with estimates ranging from $900,000.00 to $5.92 million. For the next financial year, analysts forecast that the company will post sales of $16.54 million, with estimates ranging from $860,000.00 to $38.56 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that cover Kadmon.
A number of equities analysts have issued reports on the company. ValuEngine cut Kadmon from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Cantor Fitzgerald boosted their price target on Kadmon from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Finally, Zacks Investment Research cut Kadmon from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Kadmon presently has an average rating of “Buy” and a consensus price target of $9.35.
KDMN traded up $0.41 during trading on Tuesday, hitting $4.50. The company had a trading volume of 1,720,024 shares, compared to its average volume of 2,614,435. The company has a market capitalization of $530.44 million, a PE ratio of -4.37 and a beta of 2.49. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of 0.54. Kadmon has a one year low of $1.63 and a one year high of $4.55. The firm’s 50-day moving average price is $3.54 and its 200 day moving average price is $2.64.
In other Kadmon news, major shareholder Perceptive Advisors Llc purchased 1,470,588 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $3.40 per share, with a total value of $4,999,999.20. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 2.85% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Kadmon by 23.5% in the 2nd quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock valued at $17,363,000 after acquiring an additional 1,605,568 shares in the last quarter. Vanguard Group Inc. boosted its position in Kadmon by 5.9% during the second quarter. Vanguard Group Inc. now owns 5,713,561 shares of the company’s stock valued at $11,770,000 after purchasing an additional 320,710 shares during the last quarter. Millennium Management LLC boosted its position in Kadmon by 67.8% during the third quarter. Millennium Management LLC now owns 5,168,469 shares of the company’s stock valued at $13,024,000 after purchasing an additional 2,087,903 shares during the last quarter. Boxer Capital LLC bought a new position in Kadmon in the second quarter valued at approximately $7,597,000. Finally, State Street Corp grew its stake in Kadmon by 13.7% in the third quarter. State Street Corp now owns 2,284,164 shares of the company’s stock valued at $5,756,000 after purchasing an additional 274,891 shares in the last quarter. Institutional investors own 67.25% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Featured Story: Economic Bubble
Get a free copy of the Zacks research report on Kadmon (KDMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.